Omalizumab for Chronic Urticaria, Psoriasis Care for Skin of Color, and New Global Approvals
Welcome to this week's edition of Dermatology Times' LinkedIn newsletter!
This week, we dive into findings and emerging treatments across dermatology. Highlights include the UCARE study confirming omalizumab’s safety and efficacy in treating chronic inducible urticaria and a review of therapies improving psoriasis care for skin of color. Health Canada’s approval of Zoryve foam for seborrheic dermatitis expands global treatment options, while a case series explores dupilumab's impact on pediatric patients with hyper-IgE syndrome.
If you have questions, suggestions, or would like to contribute to a future edition, please contact us via LinkedIn or via email at [email protected].
?? Breaking News Brief
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced Health Canada | Santé Canada 's approval of roflumilast (Zoryve) foam 0.3% for treating seborrheic dermatitis in patients aged 9 and older, marking the first new topical treatment in Canada with a novel mechanism of action in over 20 years. The approval is based on positive phase 3 STRATUM trial data, where 80.1% of patients achieved significant improvement by week 8.
优时比 announced the FDA approval of 2 new delivery options for bimekizumab-bkzx (Bimzelx)—a 2 mL pre-filled syringe and autoinjector—for treating moderate to severe plaque psoriasis and psoriatic arthritis. Each device contains a 320 mg dose, allowing for a more convenient single injection every 8 weeks, improving patient experience and treatment adherence.
AccureAcne, Inc. announced that the FDA has cleared its Accure Laser System for long-term treatment of mild to severe inflammatory acne vulgaris. The system, initially approved in 2022, uses a 1726 nm wavelength to target sebaceous glands, offering an innovative, non-systemic treatment. Clinical trials showed a 70% reduction in inflammatory lesions after 4 treatments, with results consistent across all skin types and acne severity levels.
LEO Pharma has launched delgocitinib (Anzupgo) cream in Germany, marking its first availability for adults with moderate to severe chronic hand eczema. This launch follows the European Commission 's approval for patients who have not responded adequately to topical corticosteroids.
?? Research Roundup
A recent open-label study assessed brevilin-A, a topical JAK inhibitor, for treating mild to moderate alopecia areata in children and adolescents. Significant hair regrowth was observed, with 46.7% of patients showing clinical improvement and 20% achieving complete remission over 6 months, alongside enhanced quality of life.
In a recent ALPHA clinical trial, investigators found that alitretinoin is more effective than ultraviolet phototherapy in reducing symptoms of chronic hand eczema after 23 weeks. The study revealed that alitretinoin provided more rapid symptom improvement, showing superiority to UV therapy by week 12. Conducted across 31 outpatient clinics in the UK, the trial included 441 participants with severe CHE unresponsive to corticosteroids.
?? Expert Insights
Explore clinical insights from: Summer Forlenza, LMFT; Chris Robb MD PHD FAAD ; and Jeffrey Stark, MD .
?? Continuing Education Opportunities
Discover ways to further your education and knowledge of specific disease states by exploring CME opportunities from Physicians' Education Resource?, LLC (PER?) below.
For more information, visit PER's website or click on the graphics below.
Thank you for reading!